Documenti di Didattica
Documenti di Professioni
Documenti di Cultura
22 Billion by 2020
from $2.29 Billion in 2015, growing at a CAGR of 22.1% from 2015
to 2020. Key factors such as
- growing pressure to curtail healthcare expenditure,
-growing demand for biosimilar drugs due to their cost-effectiveness,
rising incidences of various diseases,
- increasing number of off-patented drugs,
-positive outcomes in the ongoing clinical trials, and
rising demand for biosimilars in different therapeutic applications
such as rheumatoid arthritis and blood disorders are propelling the
growth of the global market.
However, factors such as high manufacturing complexities and
costs, stringent regulatory requirements in countries, and
innovative strategies by biologic drug manufacturers to restrict
the entry of new players are restraining the growth of this
market.
The global biosimilars market is segmented on the basis of products
and applications.
On the basis of products, the market is segmented into recombinant
nonglycosylated proteins, recombinant glycosylated proteins, and
recombinant peptides. The recombinant nonglycosylated proteins
market is further segmented into insulin, granulocyte colonystimulating factor (G-CSF), interferons, and human growth hormone;
whereas, the recombinant glycosylated proteins market is further
segmented into erythropoietin, monoclonal antibodies, and follitropin.
The recombinant peptides market is segmented into calcitonin and
glucagon. The recombinant glycosylated proteins segment is expected
to witness the highest growth rate owing to the increased demand for
the surging global cancer epidemic and the high incidence rates of
blood disorders.
Cancer cases in the world were estimated to be approximately around
14.1 million in 2012. This estimate directly reflects the resultant
increase in demand for these drugs for its application in oncology in
the coming future.
Regional Insights
The key regions taken into consideration in the biosimilars report are
North America, Europe, Asia Pacific, and rest of the world. The
European biosimilars sector is estimated to be the largest at a global
level. In 2015, the German similar biological medicinal products
market accounted for the maximum share in Europe. With respect to
the growth rate, the industry in North America is anticipated to grow
at the highest CAGR during the study period.
In the Asia Pacific region, India and China are expected to exhibit the
highest growth and emerge as the leading players in the market. Asiabased biotech companies including Celltrion Healthcare Co., Ltd.,
Biocon Ltd., and Dr. Reddys Laboratories, Inc. are actively involved
in building a stronghold in the industry, which is going to be a
significant contributing factor in pushing forward the industry growth.
Competitive Market Share Insights
Some established players in this biosimilars market are Roche
Diagnostics, Amgen, Inc., Biocon Ltd., Teva Pharmaceutical
Industries Ltd., Merck & Co., Mylan, Inc., Dr. Reddys Laboratories,
Inc., Sandoz, Inc., Celltrion Healthcare Co., Ltd., Abbvie, Inc., and
Hospira, Inc.